CPER Resist Omics aims to better understand resistance to treatments and complications associated with inflammatory and infectious diseases, in order to develop innovative and personalised therapeutic strategies; and to structure research in this field between the INFINITE, CIIL and MS2V laboratories. It is run by the University of Lille, in partnership with INSERM, the Institut Pasteur de Lille, the CNRS and the Lille University Hospital. The CPER aims to (i) maintain the competitiveness of PLBS technology platforms, through the acquisition of innovative scientific equipment; and (ii) conduct research projects to establish proofs of concept. The 2023 programming will strengthen two technological platforms (FPs), (i) the ARIADNE screening FP with the acquisition of nanodistribution equipment and the recruitment of an engineer; and (ii) BiCeL cell imaging FP with the acquisition of 2 latest generation FACS, for the development of single cell analyses. It also provides support for 9 research projects with high socio-economic valorization potential, with the objective of multiparametric optimization of molecules to lead to a drug candidate. Three of these projects will be specifically managed by the promoter presented, and will concern: the development of inhibitors in IBD; the development of modulators to treat pulmonary fibrosis and the identification of biomarkers in IBD.